Falchook, Gerald S http://orcid.org/0000-0001-9165-2191
Sachdev, Jasgit http://orcid.org/0000-0002-4408-7617
Imedio, Esteban Rodrigo http://orcid.org/0000-0001-5666-666X
Kumar, Sanjeev
Mugundu, Ganesh M
Jenkins, Suzanne
Chmielecki, Juliann
Jones, Suzanne http://orcid.org/0000-0001-6881-8050
Spigel, David R
Johnson, Melissa http://orcid.org/0000-0001-9874-1314
Funding for this research was provided by:
AstraZeneca
Article History
Received: 13 February 2023
Accepted: 4 May 2023
First Online: 12 May 2023
Statements and declarations
:
: J Chmielecki, ER Imedio, S Kumar, S Jenkins and G Mugundu are employees and shareholders of AstraZeneca plc. GS Falchook, M Johnson, S Jones and DR Spigel are employees of Sarah Cannon Research Institute. J Sachdev is an employee of HonorHealth Research Institute. GS Falchook has received speaking fees from Total Health Conferencing and Rocky Mountain Oncology Society; royalties from Wolters Kluwer; travel expenses from Bristol-Myers Squibb, EMD Serono, Fujifilm, Millennium, and Sarah Cannon Research Institute; and research funding from 3-V Biosciences, Abbisko, AbbVie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO/Eli Lilly, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, IGM Biosciences, Ignyta, ImmunoGen/MacroGenics, Incyte Corporation, Jacobio, Jounce, Kolltan, Loxo/Bayer, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Navire, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Regeneron, Rgenix, Ribon, Sapience, Silicon, Strategia, Syndax, Synthorx/Sanofi, Taiho, Takeda, Tarveda, Tesaro, Tocagen, Turning Point Therapeutics, University of Texas MD Anderson Cancer Center, Vegenics, and Xencor and has served in an advisory role for Fujifilm, Silicon, Navire, and EMD Serono.
: An independent ethics committee/institutional review board approved the final clinical study protocol, including the final version of the informed consent form and any other written information provided to the patients. This included approval of the exploratory biomarker and pharmacogenetic research and associated consent forms. This study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation, good clinical practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics.
: All participants provided written informed consent.
: N/A.